After dazzling at conference, Janssen leaders pledge to go further

16 July 2018

Janssen has been on a good run of form recently.

Its potential blockbuster depression therapy, esketamine, has been posting good trial results and its ViiV Healthcare-partnered HIV combination Juluca (dolutegravir 50g/rilpivirine 25g) received European approval in late May, all after closing on a deal to acquire Benevir Biopharma.

And then the company dazzled at ASCO, scoring two presentations in the conference’s 'best of' selection and revealing its first treatment for urothelic cancer, while in the hematology space, combining Janssen's Imbruvica (ibrutinib) with Rituxan/MabThera (rituximab) saw risk of death or symptom progression from Waldenstrom’s Macroglobulinemia fall by 80%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK